# Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

> **NCT00742027** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 129 (actual)

## Conditions studied

- Classical Hodgkin's Lymphoma

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00742027
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-16
- **Primary completion:** 2013-08-12
- **Final completion:** 2013-08-12
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742027, "Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00742027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*